anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a medicinal composition of polyinosinic cell injection and a preparation method thereof. Generally, the invention relates to a medicament for therapy or adjuvant therapy of viral keratitis, herpes simplex and chronic viral hepatitis, and particularly relates to a medicinal composition (such as an injection) prepared by using polyinosinic cells as an active ingredient, such as injection. The invention also relates to a preparation method of the medicinal composition. Specifically, the invention relates to a medicinal composition of polyinosinic cell injection. The medicinal composition comprises polyinosinic cells, an acid-base buffer agent, an osmotic pressure regulator and water. The polyinosinic cell injection has excellent medicinal properties as described in the specification.
A device for reducing a human posture dataset using density-based clustering and a method thereof, according to a preferred embodiment of the present invention, are configured to: apply a density-based clustering algorithm to a highly-redundant human posture dataset and cluster pieces of posture data, which are similar to each other; and extract only a small number of pieces of posture data from each cluster and obtain a reduced human posture dataset. Accordingly, it is possible to reduce pieces of all redundant posture data and a posture data set with high diversity. Accordingly, compared to the conventional method of learning a human posture estimation model using a conventional human posture dataset, the present invention can maintain the performance of the conventional human posture estimation model as it is even though very little data is used. Moreover, the present invention is trained through a reduced human posture dataset. As such, the present invention can demonstrate performance that is similar to that of the conventional human posture estimation model despite the fact that learning is possible in a very small amount of time compared to the time required to learn the human posture estimation model using the conventional method. In addition, it is possible to obtain a metric space from an original human posture dataset through posture analysis and perform clustering through DBSCAN, a density-based clustering algorithm, in the acquired metric space. Accordingly, the performance of clustering that groups pieces of similar posture data together can be improved.
In vitro data on metabolic interactions indicate that levetiracetam extended-release tablets are unlikely to produce, or be subject to, pharmacokinetic interactions. Levetiracetam and its major metabolite, at concentrations well above Cmax levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. 

Levetiracetam circulates largely unbound (< 10% bound) to plasma proteins; clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely. 

Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening with immediate-release levetiracetam tablets in the placebo-controlled clinical studies in epilepsy patients. The following are the results of these studies. The potential for drug interactions for levetiracetam extended-release tablets is expected to be essentially the same as that with immediate-release levetiracetam tablets.
The invention belongs to the field of biological medicine, and relates to an anti-TIGIT-PVRIG bispecific antibody, a pharmaceutical composition and application thereof. In particular, the invention relates to a bispecific antibody comprising: a first protein functional region that targets PVRIG, and a second protein functional region that targets a target different from PVRIG (e.g., TIGIT); wherein: the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; the heavy chain variable region of the PVRIG immunoglobulin comprises HCDR1 with an amino acid sequence shown as SEQ ID NO. 25, HCDR2 with an amino acid sequence shown as SEQ ID NO. 26 and HCDR3 with an amino acid sequence shown as SEQ ID NO. 27; and the light chain variable region of the PVRIG immunoglobulin comprises LCDR1 with an amino acid sequence shown as SEQ ID NO. 22, LCDR2 with an amino acid sequence shown as SEQ ID NO. 23 and LCDR3 with an amino acid sequence shown as SEQ ID NO. 24. The bispecific antibody of the invention has good anti-tumor effect.
Background: Inflammatory lesions and cysts are the most common Bartholin glands pathologic diagnoses. There have been very few reports of benign solid lesions of Bartholin glands such as nodular hyperplasia. Materials and methods: Thirty-two lesions diagnosed as Bartholin duct cyst in the gynecologic specialized institute were reviewed by two expert gynecological pathologists. Results: Using specific criteria, 7 qualified as nodular hyperplasia, 25 as Bartholin duct cyst. The average age of the patients with nodular hyperplasia was 31 years (range, 24 to 43). These lesions were solid, solid and cystic or purely cystic, had a mean maximal dimension of 3.3 cm, and were frequently thought to be Bartholin cysts on clinical examination. Four lesions were diagnosed as Bartholin duct cysts, while in the review they were considered as nodular hyperplasia. Conclusion: Nodular hyperplasia of Bartholin gland may be more common than is reported in the literature. This study showed that the diagnosis of nodular hyperplasia has been overlooked due to limited literature sources.
Sexually transmitted infections (STIs) are widespread worldwide and negatively affect sexual and reproductive health. Gaps in evidence and in available tools have long hindered STI programmes and policies, particularly in resource-limited settings. In 2022, WHO initiated a research prioritisation process to identify the most important STI research areas to address the global public health need. Using an adapted Child Health and Nutrition Research Initiative methodology including two global stakeholder surveys, the process identified 40 priority STI research needs. The top priorities centred on developing and implementing affordable, feasible, rapid point-of-care STI diagnostic tests and new treatments, especially for gonorrhoea, chlamydia, and syphilis; designing new multipurpose prevention technologies and vaccines for STIs; and collecting improved STI epidemiologic data on both infection and disease outcomes. The priorities also included innovative programmatic approaches, such as new STI communication and partner management strategies. An additional six research areas related to mpox (formerly known as monkeypox) reflect the need for STI-related research during disease outbreaks where sexual transmission can have a key role. These STI research priorities provide a call to action for focus, investment, and innovation to address existing roadblocks in STI prevention, control, and management to advance sexual and reproductive health and wellbeing for all.
Previous studies have suggested a potential association between the gut microbiota and arthritis. However, the causal links between the gut microbiota and various types of arthritis, as well as the potential mediating role of inflammatory proteins, remain unclear. Mendelian randomization was used to explore the causal relationships between gut microbiota, inflammatory proteins, and various forms of arthritis (osteoarthritis, rheumatoid and psoriatic arthritis, and ankylosing spondylitis [AS]). The inverse variance-weighted method was the primary analytical approach used. Furthermore, we examined the mediating role of inflammatory proteins in the pathway linking the gut microbiota to arthritis. Sensitivity analyses were performed to verify the robustness of the findings, and enrichment analyses were conducted to investigate the biological functions and pathways involved. We identified 11 positive and 14 negative causal effects linking the genetic liability of the gut microbiota to arthritis. Similarly, 9 positive and 8 negative causal effects between inflammatory proteins and arthritis were identified. Notably, an increased abundance of the order Bacillales (odds ratio [OR] = 1.199, 95% confidence interval [CI] = 1.030-1.394, P = 0.019) and higher interleukin-7 levels (OR = 1.322, 95% CI = 1.004-1.741, P = 0.046) significantly elevated the risk of AS. Furthermore, interleukin-7 mediated 13.8% of the effect caused by the order Bacillales, with a mediation effect size of β = 0.025 (95% CI = 0.001-0.064). Sensitivity and supplementary analyses revealed no significant evidence of horizontal pleiotropy or heterogeneity. Overall, our findings demonstrate causal links between the gut microbiota, inflammatory proteins, and four arthritis types, highlighting the gut microbiota as a potential therapeutic target. Crucially, interleukin-7 not only strongly correlated with AS but also partially mediated the effect exerted by the gut microbiota on AS, suggesting that managing the gut microbiota to modulate inflammatory proteins could serve as an effective therapeutic strategy for arthritis.
Elevated serum cholesterol is a major contributor to cardiovascular disease (CVD), which is responsible for \~1/3 of all deaths in the US. However, about 50% of those who experience heart attacks have normal cholesterol levels. Cholesterol is carried in lipoproteins (HDL, LDL, and VLDL) and the amount in circulation is used to evaluate CVD risk. However, the particle size and density of lipoprotein subfractions may be more predictive for atherogenesis than their total levels. Dietary fatty acids are well recognized modulators of lipoproteins, and ultimately CVD risk. Saturated and trans fatty acids have a negative effect on CVD risk while poly- and monounsaturated fatty acids (PUFA, MUFA) appear to be protective. The Mediterranean Diet (Med Diet) decreases atherogenic lipoproteins and reduces systemic inflammation. It is unknown how high cholesterol intake within a Med Diet will affect these parameters, although recent evidence implies that the fatty acid content of the diet is more important than the cholesterol content. Therefore, this project will evaluate the daily inclusion of whole eggs, a high cholesterol food, in the Med Diet on lipid profiles, lipoprotein particle size and density and biomarkers of systemic inflammation.
PROBLEM TO BE SOLVED: To reduce the intraocular pressure of mammals and treat especially glaucauma and ischemic retinopathy by administering a piperazinyl-heterocyclic compound. SOLUTION: A compound represented by formula I [Ar is benzisothiazolyl, quinolyl or the like; (n) is 1 or 2; X and Y, together with phenyl to which both are added, form quinolyl, 2-hydroxyquinolyl or the like], e.g. 6- 2-[4-(1-naphthyl) piperazinyl]ethyl}-benzoxazolone hydrochloride is administered. The compound represented by formula I is obtained by reacting a compound represented by formula II with a compound represented by formula III (Hal is fluoro, chloro or the like) in the presence of a weak base (e.g. triethylamine) preferably in a polar solvent at a refluxing temperature of the solvent or in the presence of a catalytic amount of sodium iodide and in the presence of a neutralizing agent for hydrogen chloride such as sodium carbonate.  When the compound represented by formula I is used for a human patient to treat glaucoma or ischemic retinopathy, the daily dose thereof is preferably 0.025-20 mg.
BACKGROUND AND AIMS: Lumbar vertebral bone attenuation, measured in Hounsfield units (HU) can indirectly indicate the bone mineral density (BMD). The aim of this study is to determine the optimal HU threshold on abdominal computed tomography (CT) scans to detect osteopathy in patients with chronic pancreatitis (CP).
METHODS: This cross-sectional study included patients with CP who underwent CT scans to measure HU at L1 to L4 vertebrae. The mean lumbar vertebral attenuation of female renal transplant donors, aged 20-30 years was utilized to calculate the T-scoreHU of all patients at each vertebral level. Receiver operator characteristic analysis was used to determine the HU and T-scoreHU for diagnosis of osteopathy in patients with CP. Dual-energy X-ray absorptiometry value was used to categorize osteopenia and osteoporosis.
RESULTS: A total of 175 patients (mean age, 34.5 ± 10.9 years; 72 % males) and 33 female renal transplant donors (mean age, 28 ± 2.4 years) were included. A threshold HU value 212 or T scoreHU of -1.80 at L1 vertebra was found to have a 78 % sensitivity and 70 % specificity for differentiating between osteoporosis and non-osteoporosis (osteopenia and normal BMD). Similarly, a threshold HU value of 254 or a T-scoreHU of -0.46 at L1 vertebra had 78 % sensitivity and 71 % specificity for distinguishing between normal and low BMD (osteoporosis and osteopenia).
CONCLUSION: Abdominal CT images, which are routinely performed in chronic pancreatitis, can be used for opportunistic screening of osteoporosis and osteopenia without additional cost or radiation exposure.
Charcot-Marie-Tooth (CMT) is a condition that potentially affects daily life function including physical activity. Currently, there is no specific treatment. To prevent physical deconditioning, physical activity recommended. Furthermore, other studies have found the benefit of being physically active, including people with neuromuscular disorders (NMD). .

Apart from the physical activity in a rehabilitation center, physical activity also needs to be maintained at the community level in people's everyday life. To measure physical activity level in the community, we need an instrument that is designed for doing so. A questionnaire can be used to collect information about type of activity, activity duration and intensity. The instruments available so far to measure physical activity at the community level are not specifically adapted to persons with CMT. Therefore, this study will focus on revising the questionnaire based on the inputs from persons with CMT themselves. Furthermore, the revised questionnaire will be compared with the original one in addition to yet another instrument.
Over 6 million Americans are living with Alzheimer's disease and related dementias and this number is expected to reach over 13 million by 2060. Thus, there is an urgent need for interventions to prevent the development and progression of Alzheimer's disease and related dementias. Regular exercise is currently the most promising strategy as it is repeatedly shown to have neuroprotective benefits. Evidence suggests that the neuroprotective effects of exercise is the result of improved health of blood vessels. Despite the vast amount of evidence on the benefit of exercise on the peripheral vasculature, there is little information regarding brain vascular responses during exercise. This study will investigate the impact of exercise at varying intensities on brain blood flow during exercise, and will also examine the influence of age and sex.

This record represents a younger cohort for the study represented in NCT05864950.
PURPOSE:To obtain a cosmetic having excellent covering power and air permeability without causing deterioration of coloring matter, oil, perfume, etc., to be blended, by blending powder consisting of spherical aggregates of hollow resin spheres, e.g. methacrylic acid ester based spheres having a specific particle diameter, etc. CONSTITUTION:A cosmetic containing spherical aggregates of hollow resin spheres having 0.01-1.0mu average particle diameter which are a copolymer of a monomer selected from a vinyl ester, vinyl ether, (meth)acrylic acid (ester), olefin and polyfunctional crosslinking monomer, e.g. ethylene glycol dimethacrylate or trivinylbenzene. This cosmetic is mainly used for makeup and advantageous to skin respiration, has excellent both covering power as well as air permeability and exhibits sufficient strength even in the case of compressing molded articles. The spherical aggregates are obtained by emulsion polymerizing the monomer, preparing a W/O/W emulsion using the resultant emulsion as seed particles, spraying and drying the formed emulsion.
The invention relates to the field of a traditional Chinese medicine combination, in particular to a traditional Chinese medicine combination for curing tinea of feet and hands and a preparation method of the traditional Chinese medicine combination. The preparation method of the traditional Chinese medicine combination for curing tinea of feet and hands comprises the following steps: mixing alums, clove, cortex pseudolaricis, chaulmoogra, cortex dictamni, garden balsam stem, Chinese honeylocust fruit, sealwort, angelica sinensis and red flower according to a weight ratio, grinding into a powder mixture; adding table vinegar in the powder mixture, and soaking for preset time or boiling. The prepared traditional Chinese medicine combination prepared from various Chinese medical herbs as raw materials adopts a soaking therapy for the diseased part of a patient with the tinea of feet and hands so as to kill pathogenic bacteria of the tinea of feet and hands in a short term, the curative effect is good, and the tinea of feet and hands does not easily recur. Moreover, the treatment cycle is short, the treatment cost is low. As the traditional Chinese medicine combination is a drug for external use, the traditional Chinese medicine combination does not have side effects on the body of the patient. By adding the table vinegar in the traditional Chinese medicine combination, the drug property of the traditional Chinese medicine combination can be enhanced, and the curative effect is more significant.
Subjects will undergo four nutritional educational classes, lasting 1 hour long, conducted over a two month period. These classes will occur on zoom and subjects will be located in their home.
In this Pro-Con commentary article, we discuss use of continuous physiologic monitoring for clinical deterioration, specifically respiratory depression in the postoperative population. The Pro position advocates for 24/7 continuous surveillance monitoring of all patients starting in the postanesthesia care unit until discharge from the hospital. The strongest arguments for universal monitoring relate to inadequate assessment and algorithms for patient risk. We argue that the need for hospitalization in and of itself is a sufficient predictor of an individual's risk for unexpected respiratory deterioration. In addition, general care units carry the added risk that even the most severe respiratory events will not be recognized in a timely fashion, largely due to higher patient to nurse staffing ratios and limited intermittent vital signs assessments (e.g., every 4 hours). Continuous monitoring configured properly using a "surveillance model" can adequately detect patients' respiratory deterioration while minimizing alarm fatigue and the costs of the surveillance systems. The Con position advocates for a mixed approach of time-limited continuous pulse oximetry monitoring for all patients receiving opioids, with additional remote pulse oximetry monitoring for patients identified as having a high risk of respiratory depression. Alarm fatigue, clinical resource limitations, and cost are the strongest arguments for selective monitoring, which is a more targeted approach. The proponents of the con position acknowledge that postoperative respiratory monitoring is certainly indicated for all patients, but not all patients need the same level of monitoring. The analysis and discussion of each point of view describes who, when, where, and how continuous monitoring should be implemented. Consideration of various system-level factors are addressed, including clinical resource availability, alarm design, system costs, patient and staff acceptance, risk-assessment algorithms, and respiratory event detection. Literature is reviewed, findings are described, and recommendations for design of monitoring systems and implementation of monitoring are described for the pro and con positions.
PROBLEM TO BE SOLVED: To provide uses of riboswitches and modified versions of riboswitches as designer genetic switches that are controlled by specific effector compounds.SOLUTION: Natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. Compounds can be used to stimulate, active, inhibit and/or inactivate riboswitches. Atomic structures of riboswitches can be used to design new compounds to stimulate, active, inhibit and/or inactivate riboswitches.
FIELD: medicine, cardiology, chemistry of peptides. SUBSTANCE: invention proposes the novel antiarrhythmic agent of the I-st class that is heptadecapeptide of the following amino acid composition: Phe-Gly-Gly-Phe-Thr- -Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asp- -Gln. This peptide is known as nocipentin. Efficiency of the proposed preparation is 10-fold more as compared with that of the known antiarrhythmic agent mexitil of the I-st class as tested in model of aconotine arrhythmias. EFFECT: enhanced effectiveness of agent. 2 tbl
Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
Subjects in the control group will be offered a free venous HbA1c test. Consistent with current practice at GOPCs, the venous sampling will be scheduled on a separate clinic visit at a set time within 1-2 weeks of recruitment. Test results will be available within one week. The subject will be informed via phone call regarding his/her DM risk, and if his/her HbA1c≥5.6%, he/she will be scheduled for a confirmatory OGTT within 2-4 weeks, ideally at the same clinic.
Placebo treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, without any emission of therapeutic dose. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Participants in the intervention group will receive two 2-hour weekly sessions, focusing on two main themes, which are "Self-awareness and self-kindness" as well as "Acceptance and non-judgmental attitude". Each session with one hour duration and have five different contents separately.